Switch theme
Sign up to access all valuation multiples
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.
2008
21
LTM Revenue n/a
LTM EBITDA n/a
$6.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genetic Analysis has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Genetic Analysis achieved revenue of $1.5M and an EBITDA of -$0.9M.
Genetic Analysis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genetic Analysis valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.4M | $1.5M | XXX | XXX | XXX |
| Gross Profit | $0.7M | $0.9M | XXX | XXX | XXX |
| Gross Margin | 51% | 61% | XXX | XXX | XXX |
| EBITDA | -$1.7M | -$0.9M | XXX | XXX | XXX |
| EBITDA Margin | -127% | -58% | XXX | XXX | XXX |
| Net Profit | -$2.7M | -$2.3M | XXX | XXX | XXX |
| Net Margin | -200% | -150% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 19, 2025, Genetic Analysis's stock price is NOK 1 (or $0).
Genetic Analysis has current market cap of NOK 71.6M (or $6.9M), and EV of NOK 68.7M (or $6.6M).
See Genetic Analysis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.6M | $6.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 19, 2025, Genetic Analysis has market cap of $6.9M and EV of $6.6M.
Genetic Analysis's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Genetic Analysis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Genetic Analysis and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $6.6M | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | -7.5x | XXX | XXX | XXX |
| P/E | -4.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -6.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGenetic Analysis's NTM/LTM revenue growth is n/a
Genetic Analysis's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged n/a for the same period.
Over next 12 months, Genetic Analysis's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Genetic Analysis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Genetic Analysis and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | -49% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | N/A | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genetic Analysis acquired XXX companies to date.
Last acquisition by Genetic Analysis was XXXXXXXX, XXXXX XXXXX XXXXXX . Genetic Analysis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Genetic Analysis founded? | Genetic Analysis was founded in 2008. |
| Where is Genetic Analysis headquartered? | Genetic Analysis is headquartered in Sweden. |
| How many employees does Genetic Analysis have? | As of today, Genetic Analysis has 21 employees. |
| Is Genetic Analysis publicy listed? | Yes, Genetic Analysis is a public company listed on SAT. |
| What is the stock symbol of Genetic Analysis? | Genetic Analysis trades under GEAN ticker. |
| When did Genetic Analysis go public? | Genetic Analysis went public in 2021. |
| Who are competitors of Genetic Analysis? | Similar companies to Genetic Analysis include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Genetic Analysis? | Genetic Analysis's current market cap is $6.9M |
| What is the current revenue growth of Genetic Analysis? | Genetic Analysis revenue growth between 2023 and 2024 was 12%. |
| Is Genetic Analysis profitable? | Yes, Genetic Analysis is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
